Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | -8.82% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.37 | N/A | -8.82% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They are focused on long-term strategies despite short-term setbacks.
Management acknowledged challenges in achieving profitability this quarter.
They emphasized ongoing efforts to improve operational efficiency.
Veracyte's disappointing EPS results indicate ongoing challenges in reaching profitability, which contributed to a 5.57% drop in stock price. Investors may be concerned about the lack of revenue data and forward guidance, suggesting uncertainty about the company's near-term prospects. The management's defensive tone reflects the difficulties they face in the current market environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WOODWARD INC
Nov 10, 2014